AstraZeneca’s vaccine contains more than 1,000 proteins derived from human cells, and EDTA helps them stay in the bloodstream. The proteins bind to a blood component called platelet factor 4 and then form structures that catalyze antibody production.
Dr. Greinacher explained his hypothesis to The Wall Street Journal May 13: When the body’s immune response is kickstarted, the vaccine can trigger an ancient defense mechanism that spirals out of control and causes bleeding and clotting.
He is working to confirm his theory and hopes drugmakers will cooperate with his efforts so he can obtain greater access to their production processes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.